Devising new strategies to track and prevent breast cancer development in BRCA mutation carriers
Joan Brugge | Harvard Ludwig Cancer Center and Harvard Medical School
- How do basal and luminal breast cells contribute to BRCA-related cancers?
- How do BRCA tumor cells evolve?
- What are the molecular defects during tumor evolution?
- How do we detection cancer evolution in carriers?
- How do we intercept and eradicate tumor development?
Dissecting early pathogenesis of BRCA1/2-associated cancer for risk prediction and prevention
Leif Ellisen | Harvard Medical School, Massachusetts General Hospital Cancer Center
- What are the early changes in cells of BRCA carrier breast tissue?
- What are the BRCA cellular vulnerabilities?
- What are tissue-based markers for prevention approaches?
Interplay and perturbations of the local microbiome and host immune system in breast cancer
Charis Eng | Cleveland Clinic
- What are the differences in microbes found with normal versus BRCA breast cancers?
- How do microbes contribute to immune changes and cancer?
- Could microbiome engineering prevent cancer?
Determinants of immune activity and molecular features in BRCA1/2 mutation carriers
Katherine Nathanson | University of Pennsylvania
- What are the immune functional status in BRCA carriers?
- Are there associations between molecular and immune status with therapeutic response and survival?
Dissection of BRCA-mediated Tumor Suppression Pathways
Patrick Sung | Univ. of Texas Health Science Center at San Antonio
- What are the regulators of BRCA function?
- What are BRCA-independent DNA repair pathways?
- What are the DNA repair mechanisms?
- What are the drug vulnerabilities of BRCA deficient cells?
Early detection of cancer in high-risk BRCA mutation carriers using liquid biopsies
Victor Velculescu | Johns Hopkins University
- What are the molecular characteristics of circulation free DNA in BRCA carriers with and without cancer?
- What is the strategy for screening?